American Trust Invests $252,000 in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

American Trust bought a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,163 shares of the medical device company’s stock, valued at approximately $252,000.

Several other hedge funds also recently made changes to their positions in the business. BlackRock Inc. increased its holdings in shares of Tandem Diabetes Care by 0.8% during the first quarter. BlackRock Inc. now owns 6,531,074 shares of the medical device company’s stock worth $759,496,000 after purchasing an additional 52,436 shares during the period. Vanguard Group Inc. increased its holdings in shares of Tandem Diabetes Care by 2.4% during the first quarter. Vanguard Group Inc. now owns 6,306,724 shares of the medical device company’s stock worth $733,408,000 after purchasing an additional 146,577 shares during the period. Capital World Investors increased its holdings in shares of Tandem Diabetes Care by 4.0% during the fourth quarter. Capital World Investors now owns 3,427,129 shares of the medical device company’s stock worth $515,851,000 after purchasing an additional 133,133 shares during the period. Invesco Ltd. increased its holdings in shares of Tandem Diabetes Care by 7.1% during the first quarter. Invesco Ltd. now owns 2,080,173 shares of the medical device company’s stock worth $241,904,000 after purchasing an additional 137,202 shares during the period. Finally, State Street Corp increased its stake in Tandem Diabetes Care by 3.6% in the first quarter. State Street Corp now owns 1,708,030 shares of the medical device company’s stock valued at $198,627,000 after acquiring an additional 59,778 shares during the last quarter. 95.28% of the stock is owned by institutional investors.

Tandem Diabetes Care Price Performance

TNDM stock opened at $57.26 on Monday. The firm has a market cap of $3.68 billion, a price-to-earnings ratio of -260.27 and a beta of 0.95. The company has a quick ratio of 5.36, a current ratio of 6.00 and a debt-to-equity ratio of 0.63. Tandem Diabetes Care, Inc. has a 12-month low of $42.90 and a 12-month high of $155.86. The company’s fifty day simple moving average is $55.02 and its 200 day simple moving average is $76.13.

Analysts Set New Price Targets

A number of research analysts recently issued reports on TNDM shares. Lake Street Capital decreased their price objective on shares of Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. Piper Sandler decreased their price objective on shares of Tandem Diabetes Care from $120.00 to $80.00 and set an “overweight” rating on the stock in a research note on Thursday, August 4th. TheStreet cut shares of Tandem Diabetes Care from a “c-” rating to a “d+” rating in a research note on Monday, June 13th. Raymond James decreased their target price on shares of Tandem Diabetes Care from $125.00 to $90.00 and set an “outperform” rating on the stock in a research note on Thursday, August 4th. Finally, StockNews.com cut shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research note on Friday, September 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus price target of $103.36.

About Tandem Diabetes Care

(Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Stories

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.